Evaxion Biotech A/S ADR (EVAX)

$1.66 +0.02 (1.22%)
Market Cap 2.30M
Revenue (ttm) 3.34M
Net Income (ttm) -10.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -316.47%
Debt to Equity Ratio -4.95
Volume 57,600
Avg Vol 68,002
Day's Range N/A - N/A
Shares Out 1.40M
Stochastic %K 76%
Beta -0.24
Analysts Strong Sell
Price Target $13.25

Company Profile

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a m...

Industry: Biotechnology
Sector: Healthcare
Phone: 45 53 53 18 50
Website: evaxion.ai
Address:
Dr. Neergaards Vej, 5th Floor, Horsholm, Denmark
Manwiththeplan
Manwiththeplan Apr. 25 at 5:44 AM
$EVAX EVAX Reiterated by HC Wainwright & Co. -- Price Target Maintaine https://share.google/Oh3grjck1wzOvfGdH
0 · Reply
lestatk
lestatk Apr. 21 at 2:53 PM
$EVAX
0 · Reply
Johnnyshots
Johnnyshots Apr. 21 at 11:56 AM
$EVAX
0 · Reply
JLCw
JLCw Apr. 19 at 8:16 PM
Main list for Monday $TOVX $BEAT $IPW $EVAX $YYGH All sitting close to trigger levels with volume potential. Watching for breaks and confirmation JL
0 · Reply
Manwiththeplan
Manwiththeplan Apr. 19 at 6:15 PM
$EVAX i think this will only go up coming 6 months
1 · Reply
Mandano
Mandano Apr. 18 at 3:25 AM
$EVAX the market will understand what their research means soon. Good times ahead.
0 · Reply
Tigerz11
Tigerz11 Apr. 17 at 9:39 PM
$EVAX next week
1 · Reply
focafoca99
focafoca99 Apr. 17 at 8:02 PM
$EVAX said new phase 2 EVX-01 data showed 86% of selected vaccine targets triggered tumor-specific immune responses, supporting its AI-Immunology platform in personalized cancer vaccines.
0 · Reply
Manwiththeplan
Manwiththeplan Apr. 17 at 7:29 PM
$EVAX evaxion is curing cancer. Marcet cap 40 million..
0 · Reply
JLCw
JLCw Apr. 17 at 7:23 PM
$EVAX strong AI cancer vaccine data just dropped, showing ~86% precision on targets triggering immune response + AACR presentation next Wednesday
0 · Reply
Latest News on EVAX
Evaxion's AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial

Apr 17, 2026, 3:10 PM EDT - 8 days ago

Evaxion's AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial

Evaxion concludes Annual General Meeting

Apr 16, 2026, 11:30 AM EDT - 9 days ago

Evaxion concludes Annual General Meeting

Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress

Mar 30, 2026, 8:00 AM EDT - 26 days ago

Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress

Notice to convene Evaxion's Annual General Meeting

Mar 19, 2026, 9:00 AM EDT - 5 weeks ago

Notice to convene Evaxion's Annual General Meeting

Evaxion announces business update and full year 2025 financial results

Mar 5, 2026, 9:28 AM EST - 7 weeks ago

Evaxion announces business update and full year 2025 financial results

Evaxion plans to file 2025 annual report later today

Mar 5, 2026, 8:02 AM EST - 7 weeks ago

Evaxion plans to file 2025 annual report later today

Evaxion to announce business update and full year 2025 financial results on March 5, 2026

Mar 2, 2026, 8:00 AM EST - 7 weeks ago

Evaxion to announce business update and full year 2025 financial results on March 5, 2026

Evaxion expands AI-Immunology™ platform into autoimmune diseases

Jan 13, 2026, 8:00 AM EST - 3 months ago

Evaxion expands AI-Immunology™ platform into autoimmune diseases

Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week

Jan 7, 2026, 8:00 AM EST - 3 months ago

Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week

Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out

Dec 19, 2025, 12:43 PM EST - 4 months ago

Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out

Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2

Dec 19, 2025, 7:00 AM EST - 4 months ago

Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2

Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting

Dec 6, 2025, 2:00 PM EST - 5 months ago

Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting

Evaxion announce 2026 financial calendar

Nov 12, 2025, 8:00 AM EST - 5 months ago

Evaxion announce 2026 financial calendar

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Nov 7, 2025, 5:10 PM EST - 6 months ago

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Evaxion announces business update and third quarter 2025 financial results

Nov 6, 2025, 7:30 AM EST - 6 months ago

Evaxion announces business update and third quarter 2025 financial results

Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

Nov 3, 2025, 9:00 AM EST - 6 months ago

Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Oct 31, 2025, 9:05 AM EDT - 6 months ago

Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Oct 31, 2025, 8:00 AM EDT - 6 months ago

Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Evaxion raises $7.2 million, extending cash runway to second half of 2027

Oct 30, 2025, 8:00 AM EDT - 6 months ago

Evaxion raises $7.2 million, extending cash runway to second half of 2027

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

Oct 27, 2025, 8:00 AM EDT - 6 months ago

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Oct 17, 2025, 8:15 AM EDT - 6 months ago

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Oct 13, 2025, 8:00 AM EDT - 6 months ago

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Evaxion expands AI-Immunology™ platform with automated vaccine design module

Oct 8, 2025, 8:12 AM EDT - 7 months ago

Evaxion expands AI-Immunology™ platform with automated vaccine design module

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

Oct 3, 2025, 9:00 AM EDT - 7 months ago

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

Sep 25, 2025, 7:00 AM EDT - 7 months ago

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Aug 11, 2025, 8:00 AM EDT - 9 months ago

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Jul 25, 2025, 9:00 AM EDT - 9 months ago

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Evaxion finalizes agreement with EIB to convert debt into equity

Jul 11, 2025, 8:00 AM EDT - 10 months ago

Evaxion finalizes agreement with EIB to convert debt into equity

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Jul 1, 2025, 8:30 AM EDT - 10 months ago

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Jun 25, 2025, 8:00 AM EDT - 10 months ago

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Evaxion receives grant funding to design new polio vaccine

Jun 3, 2025, 9:15 AM EDT - 11 months ago

Evaxion receives grant funding to design new polio vaccine

Evaxion announces business update and first quarter 2025 financial results

May 27, 2025, 7:30 AM EDT - 11 months ago

Evaxion announces business update and first quarter 2025 financial results

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

May 23, 2025, 8:00 AM EDT - 1 year ago

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

May 22, 2025, 8:00 AM EDT - 1 year ago

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Apr 28, 2025, 8:00 AM EDT - 1 year ago

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Evaxion to present at World Vaccine Congress

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Evaxion to present at World Vaccine Congress

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Feb 25, 2025, 8:00 AM EST - 1 year ago

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Evaxion announces closing of $10.8 million public offering

Jan 31, 2025, 4:05 PM EST - 1 year ago

Evaxion announces closing of $10.8 million public offering

Evaxion announces pricing of $10.8 million public offering

Jan 30, 2025, 8:00 AM EST - 1 year ago

Evaxion announces pricing of $10.8 million public offering

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Jan 28, 2025, 8:15 AM EST - 1 year ago

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Evaxion announces completion of ADS ratio change

Jan 14, 2025, 4:05 PM EST - 1 year ago

Evaxion announces completion of ADS ratio change

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Jan 10, 2025, 8:00 AM EST - 1 year ago

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Evaxion announces plan to implement ADS ratio change

Dec 30, 2024, 8:00 AM EST - 1 year ago

Evaxion announces plan to implement ADS ratio change

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Nov 12, 2024, 8:00 AM EST - 1 year ago

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Evaxion announces business update and third quarter 2024 financial results

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Evaxion announces business update and third quarter 2024 financial results

Evaxion to announce business update and third quarter 2024 financial results on October 31

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Evaxion to announce business update and third quarter 2024 financial results on October 31

Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials

Oct 9, 2024, 8:00 AM EDT - 1 year ago

Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform

Oct 3, 2024, 8:00 AM EDT - 1 year ago

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform

Manwiththeplan
Manwiththeplan Apr. 25 at 5:44 AM
$EVAX EVAX Reiterated by HC Wainwright & Co. -- Price Target Maintaine https://share.google/Oh3grjck1wzOvfGdH
0 · Reply
lestatk
lestatk Apr. 21 at 2:53 PM
$EVAX
0 · Reply
Johnnyshots
Johnnyshots Apr. 21 at 11:56 AM
$EVAX
0 · Reply
JLCw
JLCw Apr. 19 at 8:16 PM
Main list for Monday $TOVX $BEAT $IPW $EVAX $YYGH All sitting close to trigger levels with volume potential. Watching for breaks and confirmation JL
0 · Reply
Manwiththeplan
Manwiththeplan Apr. 19 at 6:15 PM
$EVAX i think this will only go up coming 6 months
1 · Reply
Mandano
Mandano Apr. 18 at 3:25 AM
$EVAX the market will understand what their research means soon. Good times ahead.
0 · Reply
Tigerz11
Tigerz11 Apr. 17 at 9:39 PM
$EVAX next week
1 · Reply
focafoca99
focafoca99 Apr. 17 at 8:02 PM
$EVAX said new phase 2 EVX-01 data showed 86% of selected vaccine targets triggered tumor-specific immune responses, supporting its AI-Immunology platform in personalized cancer vaccines.
0 · Reply
Manwiththeplan
Manwiththeplan Apr. 17 at 7:29 PM
$EVAX evaxion is curing cancer. Marcet cap 40 million..
0 · Reply
JLCw
JLCw Apr. 17 at 7:23 PM
$EVAX strong AI cancer vaccine data just dropped, showing ~86% precision on targets triggering immune response + AACR presentation next Wednesday
0 · Reply
Lenni_D
Lenni_D Apr. 17 at 7:16 PM
$EVAX As always the science is amazing. They can probably cure every disease in the world 🙂 But what we need are partnerships.
1 · Reply
Lenni_D
Lenni_D Apr. 17 at 7:13 PM
$EVAX Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response The results reinforce that Evaxion’s pioneering AI platform, AI-Immunology™ accurately identifies and selects the most relevant vaccine targets Data will be presented at the American Association for Cancer Research (AACR) Annual Meeting https://evaxion.ai/investors/press-releases/?press_release_id=11106
0 · Reply
AlertsAndNews
AlertsAndNews Apr. 17 at 7:12 PM
$EVAX not a ton of volume but a headline here Evaxion's AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial
0 · Reply
Lenni_D
Lenni_D Apr. 17 at 7:05 PM
$EVAX New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma https://evaxion.ai/investors/press-releases/?press_release_id=11091
0 · Reply
focafoca99
focafoca99 Apr. 16 at 7:15 PM
$EVAX shareholders approved the annual report and board proposals at its annual general meeting.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 14 at 1:49 AM
$EVAX RSI: 57.65, MACD: 0.1071 Vol: 0.17, MA20: 3.84, MA50: 3.54 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
baldaldo
baldaldo Apr. 9 at 3:59 PM
$EVAX Can we get some volume?
1 · Reply
Manwiththeplan
Manwiththeplan Apr. 8 at 5:05 PM
$EVAX
0 · Reply
focafoca99
focafoca99 Apr. 7 at 9:30 PM
$EVAX completed the last patient visit in the one-year extension of its Phase 2 EVX-01 cancer-vaccine trial.
0 · Reply
TheTradeXchange
TheTradeXchange Apr. 7 at 12:01 PM
$EVAX - Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01
0 · Reply
Manwiththeplan
Manwiththeplan Apr. 1 at 4:28 PM
$EVAX Form 3/A Evaxion A/S For: Mar 18 Filed by: TAYTON-MARTIN HELEN KATRINA https://share.google/nZi2F2dPn7MFiqnuM CEO is owner of a large part of evaxion
1 · Reply
Manwiththeplan
Manwiththeplan Mar. 31 at 4:10 PM
$EVAX pipeline is awesome
1 · Reply